Biogen to cut work force by 13 percent

Wed, 11/03/2010 - 4:34am
Mass High Tech: The Journal of New England Technology

Biogen Idec Inc., the second largest biotechnology company in Massachusetts with approved blockbuster drugs to treat Multiple Sclerosis, has announced it will cut its work force by 13 percent, closing a site in San Diego and consolidating sites in Eastern Massachusetts into the large sites in Weston and Cambridge. The company said it would save $300 million per year through the restructuring. The company expects to take a one-time restructuring charge of $115 million.

Biogen (Nasdaq: BIIB) plans to narrow its research focus to neurology, and abandon its programs in cardiovascular medicine. It will seek to divest its oncology assets.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.